Section Menu

700112 | 7α-hydroxycholestenone-d7

7α-hydroxy-4-cholesten-3-one-d7

7α-hydroxycholestenone-d7

Powder

Size SKU Packaging Price
1mg 700112P-1mg 700112P-1mg 1 x 1mg $808.14
10mg 700112P-10mg 700112P-10mg 1 x 10mg $5,719.10
Request Bulk Pricing
Info

7α-hydroxycholestenone-d7

7α-hydroxy-4-cholesten-3-one-d7

7α-Hydroxy-4-cholesten-3-one is an intermediate in the biochemical synthesis of bile acids from cholesterol. Its precursor, 7α-hydroxycholesterol, is produced from cholesterol by hepatic cholesterol 7α-hydroxylase (CYP7A1).[1]
It is metabolized by the enzyme 7α-hydroxycholest-4-en-3-one 12α-hydroxylase to 7α,12α-dihydroxycholest-4-en-3-one and then to cholic acid, the major primary bile acid in humans. Alternatively, it can be converted into 5β-cholestane-3α,7α-diol and then to chenodeoxycholic acid, the other major primary bile acid in humans.
Serum 7α-hydroxy-4-cholesten-3-one concentrations reflect the activity of the bile acid synthetic pathway. Serum 7α-hydroxy-4-cholesten-3-one values vary during the day as bile acid synthetic rates have a diurnal rhythm.[2]
Elevated values are found in patients with bile acid malabsorption and may be useful in the diagnosis of this condition as high values are associated with low SeHCAT retention.[3] The increase in serum 7α-hydroxy-4-cholesten-3-one concentrations reflects the loss of bile acids secondary to bile acid malabsorption or the increased synthesis found in primary bile acid diarrhea associated with impaired negative feedback of CYP7A1 by FGF19.[4]
[1] Russell, D.W. (2003). The enzymes, regulation, and genetics of bile acid synthesis. Annual review of biochemistry 72: 137–74.
[2] Gälman, C., Angelin, B., Rudling, M. (2005). Bile acid synthesis in humans has a rapid diurnal variation that is asynchronous with cholesterol synthesis. Gastroenterology 129 (5): 1445–53.
[3] Brydon, W.G., Nyhlin, H., Eastwood, M.A., Merrick, M.V. (1996). Serum 7 alpha-hydroxy-4-cholesten-3-one and selenohomocholyltaurine (SeHCAT) whole body retention in the assessment of bile acid induced diarrhoea. European journal of gastroenterology & hepatology 8 (2): 117–23.
[4] Hofmann, A.F., Mangelsdorf, D.J., Kliewer, S.A. (2009). Chronic diarrhea due to excessive bile acid synthesis and not defective ileal transport: a new syndrome of defective fibroblast growth factor 19 release. Clinical gastroenterology and hepatology 7 (11): 1151–4.
Data
Hygroscopic
No
Light Sensitive
No
Molecular Formula
C27H37D7O2
Percent Composition
C 79.54%, H 12.61%, O 7.85%
Purity
>99%
Stability
1 Year
Storage Temperature
-20°C
CAS Number
2260669-17-6
CAS Registry Number is a Registered Trademark of the American Chemical Society
Formula Weight
407.68
Exact Mass
407.378
Synonyms
25,26,26,26,27,27,27-heptadeutero-7α-hydroxy-4-cholesten-3-one
111106
Downloads
References

Brydon WG, Culbert P, Kingstone K, Jarvie A, Iacucci M, Tenhage M, Ghosh S. An evaluation of the use of serum 7-alpha-hydroxycholestenone as a diagnostic test of bile acid malabsorption causing watery diarrhea. Can J Gastroenterol. 2011 Jun;25(6):319-23. doi: 10.1155/2011/701287. PMID: 21766092; PMCID: PMC3142604.

 PubMed ID: 21766092

Russell DW. The enzymes, regulation, and genetics of bile acid synthesis. Annu Rev Biochem. 2003;72:137-74. doi: 10.1146/annurev.biochem.72.121801.161712. Epub 2003 Jan 16. PMID: 12543708.

 PubMed ID: 12543708

Gälman C, Angelin B, Rudling M. Bile acid synthesis in humans has a rapid diurnal variation that is asynchronous with cholesterol synthesis. Gastroenterology. 2005 Nov;129(5):1445-53. doi: 10.1053/j.gastro.2005.09.009. PMID: 16285946.

 PubMed ID: 16285946

Brydon WG, Nyhlin H, Eastwood MA, Merrick MV. Serum 7 alpha-hydroxy-4-cholesten-3-one and selenohomocholyltaurine (SeHCAT) whole body retention in the assessment of bile acid induced diarrhoea. Eur J Gastroenterol Hepatol. 1996 Feb;8(2):117-23. doi: 10.1097/00042737-199602000-00005. PMID: 8723414.

 PubMed ID: 8723414

Hofmann AF, Mangelsdorf DJ, Kliewer SA. Chronic diarrhea due to excessive bile acid synthesis and not defective ileal transport: a new syndrome of defective fibroblast growth factor 19 release. Clin Gastroenterol Hepatol. 2009 Nov;7(11):1151-4. doi: 10.1016/j.cgh.2009.07.026. Epub 2009 Aug 7. PMID: 19665580; PMCID: PMC2850200.

 PubMed ID: 19665580
Certificates of Analysis

Related Products

700194
7α-Hydroxy-3-oxocholest-4-enoic acid-d3 7α-Hydroxy-3-oxocholest-4-enoic acid-d3 Buy Now
700136
7α,27-dihydroxycholesterol-d6 7α,27-dihydroxycholesterol-d6 Buy Now
700078
7α,25-dihydroxycholesterol-d6 7α,25-dihydroxycholesterol-d6 Buy Now
700059
27-hydroxycholesterol-d6 27-hydroxycholesterol-d6 Buy Now

Cart

Item Price Qty.
${ item.sku }
Base Price: $${ (item.price - (item.options.custompackaging * 4.2 + (item.options.custompackaging > 50 ? 250 : 150))).toFixed(2) }
Custom Packaging: +${ (item.options.custompackaging * 4.2 + (item.options.custompackaging > 50 ? 250 : 150)).toFixed(2) }
Change Custom Packaging 		$ ${ item.total.toFixed(2) }
Subtotal: ${ cart.itemSubtotal|money }
${ adjustment.name } ${ adjustment.amountAsCurrency }
Order Total: ${ cart.totalPriceAsCurrency }
Finalize Cart